This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. Under the agreement,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology )
Also on site :
- Author Gets Honest About LeBron James, Michael Jordan's Legacy in New Book
- Diego Segui Passes Away
- Son of Rock Royalty Drops Out of Black Sabbath's Historic Farewell Show